Form 4: Daxor Corp: Director Granted Stock Options

Daxor Corp director Joy S. Goudie was granted stock options contingent on SEC approval of an amended incentive plan.

Summary

• Director Joy S. Goudie of Daxor Corp was granted 2,500 stock options with an exercise price of $10.14.
• The grant is contingent upon the SEC's approval to amend the Daxor Corporation 2020 Incentive Compensation Plan.
• The stock options are set to vest in three installments: 833 on June 23, 2026, 883 on June 23, 2027, and 834 on June 23, 2028.
• The options have an expiration date of June 23, 2031.
• This transaction was reported on June 25, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details a standard director compensation event contingent on regulatory approval, with no immediate financial impact or significant strategic shift.

Positives

• Director compensation through stock options can align management interests with shareholder value.
• The grant of options suggests confidence in the company's future prospects, pending regulatory approval.

Negatives

• The stock options are contingent on SEC approval, introducing uncertainty.
• The vesting schedule is spread over several years, meaning immediate impact on ownership is limited.

Risks

• The primary risk is the failure to obtain SEC approval for the amended incentive plan, which would invalidate the option grant.
• Market volatility could impact the value of the stock options if the share price does not exceed the exercise price of $10.14 by expiration.

Future Outlook

The future outlook for the stock options is dependent on SEC approval of the amended incentive plan and the company's stock performance relative to the $10.14 exercise price.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and healthcare sectors, often used as a long-term incentive to retain talent and align executive interests with shareholder value, especially in companies reliant on regulatory approvals.

Corporate Governance

Related Party Transactions

• Grant of stock options to Director Joy S. Goudie.

Stakeholder Impact

• Shareholders: The grant of options could lead to future dilution if exercised, but also aligns director incentives with long-term share price appreciation.
• Employees: The amended incentive plan, if approved, may set a precedent for future employee compensation structures.
• Management: Directors benefit from potential future gains on stock options.

Next Steps

• Await SEC approval for the amendment to the Daxor Corporation 2020 Incentive Compensation Plan.
• Monitor the vesting schedule of the stock options.

Key Dates

Keywords

stock options, Daxor Corp, DXR, SEC approval, incentive plan, director compensation, insider trading, Form 4